CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUPPLY AND LICENSE AGREEMENT BETWEEN SERUM INSTITUTE OF INDIA PRIVATE...Supply and License Agreement • November 10th, 2020 • Novavax Inc • Biological products, (no disgnostic substances)
This Supply and License Agreement (the “Agreement”) is entered into and made effective as of July 30, 2020 (the “Effective Date”), by and between Serum Institute of India Private Limited., an Indian company having its principal place of business at 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates). Novavax and SIIPL may each be referred to herein individually as a “Party” and collectively as the “Parties.”
BASE AGREEMENT BETWEEN ADVANCED TECHNOLOGY INTERNATIONAL (ATI) SUMMERVILLE, SC 29486 AND Novavax, Inc. Gaithersburg, MD 20878Agreement • November 10th, 2020 • Novavax Inc • Biological products, (no disgnostic substances) • South Carolina
This Agreement is entered into between the Advanced Technology International hereinafter referred to as the ''Consortium Management Firm (CMF)," and Novavax, Inc ., hereinafter referred to as "Project Agreement Holder." This Agreement constitutes the entire understanding and agreement between the parties with respect to the subject matter hereof and supersedes all prior representations and agreements. It shall not be varied except by an instrument in writing of subsequent dale duly executed by an authorized representative of each of the parties. The validity, construction, scope and performance or this Agreement shall be governed by the laws or the stale of South Carolina, excluding its choice of laws rules .
CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Amendment to SUPPLY AND LICENSE AGREEMENT DATED 30 JULY 2020 (“Agreement”)...Supply and License Agreement • November 10th, 2020 • Novavax Inc • Biological products, (no disgnostic substances)
This Amendment (“Amendment”) to the SUPPLY AND LICENSE AGREEMENT dated July 30, 2020 (“Agreement”), is entered into between Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates) and Serum Institute of India Private Limited, a company incorporated under the Companies Act, 1956 with registration number U80903PN1984PTC03294, and having its registered address as 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and is entered into and made effective as of September 11, 2020 (“Effective Date of Amendment”). All capitalized terms or otherwise undefined terms herein this Amendment shall have the same meaning and interpretation as in the Agreement
CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Novavax Inc • November 10th, 2020 • Biological products, (no disgnostic substances)
This Undefinitized Project Agreement is awarded under the authority of MCDC Base Agreement No. 2020-530, and herein incorporates all the terms and conditions thereof.
